Elekta (OTCMKTS:EKTAY) Sees Unusually-High Trading Volume – Here’s What Happened

Elekta AB (OTCMKTS:EKTAY) saw strong trading volume on Thursday . 8,873 shares changed hands during mid-day trading, an increase of 209% from the previous session’s volume of 2,867 shares.The stock last traded at $5.08 and had previously closed at $5.1950.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Elekta from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Elekta Stock Down 2.2%

The company has a market capitalization of $1.87 billion, a PE ratio of -42.33 and a beta of 1.05. The company has a quick ratio of 0.68, a current ratio of 0.87 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average of $5.27 and a two-hundred day moving average of $5.59.

Elekta (OTCMKTS:EKTAY) last announced its quarterly earnings data on Thursday, August 27th. The company reported $0.07 earnings per share for the quarter. The firm had revenue of $372.30 million during the quarter. Elekta had a negative net margin of 2.38% and a positive return on equity of 13.31%. Equities research analysts predict that Elekta AB will post 0.43 earnings per share for the current fiscal year.

About Elekta

Elekta AB is a Sweden-based medical technology company focused on radiation oncology and precision treatment solutions. The company develops and supplies systems used to diagnose, plan and deliver treatments for cancer and other conditions affecting the brain and nervous system.

Its product portfolio includes linear accelerators for external-beam radiotherapy, stereotactic radiosurgery systems such as Leksell Gamma Knife, brachytherapy equipment and treatment-planning, oncology information and workflow software.